Video

Dr. Bradley on Evolving Therapeutic Strategies in MPNs

Terrence J. Bradley, MD, discusses the evolution of therapeutic strategies in myeloproliferative neoplasms.

Terrence J. Bradley, MD, assistant professor, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the evolution of therapeutic strategies in myeloproliferative neoplasms (MPNs).

Interferon is used for a variety of malignancies, says Bradley; this is an injectable therapy that is effective, but not well tolerated. Patients with MPNs who receive interferon treatment often experience viral, flu-like symptoms, as well as depression, fever, and joint aches. Due to these symptoms, most patients cannot stay on that type of therapy for a prolonged period of time, adds Bradley.

The field of MPNs is going to shift to use of more oral and selective agents. More epigenetic targeted therapies will emerge in the future, predicts Bradley. Drugs, such as interferon, have already become an afterthought, according to Bradley; these agents are mainly used in patients who do not have any other options available or those who are pregnant because that is the only known safe therapy option. The field is going to see many new oral, active, selective, and safe agents forthcoming, concludes Bradley.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity